19:32 , Jan 20, 2017 |  BC Week In Review  |  Company News

APT Therapeutics, AZ deal

The companies partnered to develop APT's APT102 . APT will receive an upfront payment and is eligible for development milestones. AstraZeneca, which has an option to acquire the product, will fund trials of APT102 to...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3; CD39L3) In vitro and canine studies suggest engineered ENTPD3 can help prevent thrombosis. Extracellular ATP, which has proinflammatory...
07:00 , Aug 1, 2005 |  BC Week In Review  |  Company News

ParinGenix management update

ParinGenix Inc. , Tucson, Ariz.   Business: Cardiovascular   Hired: Eric Leire as CEO, formerly president and CEO at APT Therapeutics Inc.  ...